

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/081105 A3

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 413/14 (2006.01)
C07D 403/06 (2006.01) C07D 473/34 (2006.01)
C07D 403/12 (2006.01) C07D 473/36 (2006.01)
C07D 403/14 (2006.01) A61K 31/395 (2006.01)
C07D 409/14 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/GB2008/004171

(22) International Filing Date:

17 December 2008 (17.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0725030.1 21 December 2007 (21.12.2007) GB
0815177.1 19 August 2008 (19.08.2008) GB

(71) Applicant (for all designated States except US): **UCB PHARMA S.A.** [BE/BE]; 60 Allée de la Recherche, B-1070 Brussels (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALLEN, Daniel, Rees** [GB/GB]; BioFocus DPI, Chesterford Research Park, Saffron Walden, Essex CB10 1XL (GB). **BUCKLEY, George, Martin** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **BÜRLI, Roland** [CH/GB]; BioFocus DPI, Chesterford Research Park, Saffron Walden, Essex CB10 1XL (GB). **DAVENPORT, Richard, John** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **KINSELLA, Natasha** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **LOCK, Christopher, James** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **LOWE, Christopher** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **MACK, Stephen, Robert** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **PITT, William, Ross** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **RATCLIFFE, Andrew, James** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **RICHARD, Marianna, Dilani** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road,

Slough, Berkshire SL1 3WE (GB). **SABIN, Verity, Margaret** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **SHARPE, Andrew** [GB/GB]; BioFocus DPI, Chesterford Research Park, Saffron Walden, Essex CB10 1XL (GB). **TAIT, Laura, Jane** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **WARRELOW, Graham, John** [GB/GB]; UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **WILLIAMS, Sophie, Caroline** [GB/GB]; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(74) Agent: **THOMPSON, John**; UCB CELLTECH, 208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

20 August 2009

(54) Title: QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS

(57) Abstract: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.



WO 2009/081105 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2008/004171

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D401/14 C07D403/06 C07D403/12 C07D403/14 C07D409/14
C07D413/14 C07D473/34 C07D473/36 A61K31/395 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VEKARIYA N A ET AL: "Synthesis of isoxazoles and quinoxalines as potential anticancer agents" INDIAN JOURNAL OF CHEMISTRY. SECTION B: ORGANIC AND MEDICINAL CHEMISTRY, SCIENTIFIC PUBLISHERS, JODHPUR, IN, vol. 42B, no. 2, 1 February 2003 (2003-02-01), pages 421-424, XP009114228 ISSN: 0376-4699 cited in the application page 422; table 1; compounds 2A-2F, 2H-3F, 3H-3L page 421</p> <p style="text-align: center;">----- -/--</p>	1-15

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

17 April 2009

Date of mailing of the international search report

26/06/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Jeanjean, Fabien

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2008/004171

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	STARKE I ET AL: "Evidence for an aryl migration during the electron impact induced fragmentation of substituted aryloxymethylquinoxalines." RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2002, vol. 16, no. 3, 2002, pages 169-175, XP002524133 ISSN: 0951-4198 page 170; compound 34 -----	1-15
X	DD 258 228 A1 (FAHLBERG LIST VEB [DD]) 13 July 1988 (1988-07-13) cited in the application page 2; compound II -----	6
A	WO 2007/088999 A (TANABE SEIYAKU CO [JP]; NAKAMURA YOSHINORI [JP]; HAYASHI NORIMITSU [JP]) 9 August 2007 (2007-08-09) page 207; claim 13 -----	1-5,7-15
A	WO 2007/030360 A (APPLIED RESEARCH SYSTEMS [NL]; PALMER STEPHEN S [US]; NATARAJA SELVARA) 15 March 2007 (2007-03-15) page 44; claim 15; compounds (V), (VI) -----	1-15
A	WO 2007/129052 A (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; DAVID LAURENT [SE]; FOOT) 15 November 2007 (2007-11-15) page 79; claim 1; compound II -----	1-15
A	WO 2007/079999 A (ZENTARIS GMBH [DE] AETERNA ZENTARIS GMBH [DE]) 19 July 2007 (2007-07-19) page 187; claim 1 -----	1-15
P,X	WO 2008/118455 A (AMGEN INC [US]) 2 October 2008 (2008-10-02) cited in the application page 69; claim 1 -----	1-15
P,X	WO 2008/118468 A (AMGEN INC [US]) 2 October 2008 (2008-10-02) cited in the application page 241; claim 1 -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2008/004171

Patent document cited in search report	A1	Publication date	Patent family member(s)	Publication date
DD 258228	A1	13-07-1988	NONE	
WO 2007088999	A	09-08-2007	AR 059248 A1 EP 1979341 A1 US 2009023729 A1 UY 30118 A1	19-03-2008 15-10-2008 22-01-2009 29-06-2007
WO 2007030360	A	15-03-2007	AU 2006287765 A1 CA 2618489 A1 EC SP088245 A KR 20080052641 A	15-03-2007 15-03-2007 28-04-2008 11-06-2008
WO 2007129052	A	15-11-2007	EP 2016068 A1	21-01-2009
WO 2007079999	A	19-07-2007	AR 056216 A1 AU 2006334721 A1 CA 2628186 A1 CN 101330918 A EP 1790342 A1 EP 1962854 A2 KR 20080068116 A US 2007123494 A1	26-09-2007 19-07-2007 19-07-2007 24-12-2008 30-05-2007 03-09-2008 22-07-2008 31-05-2007
WO 2008118455	A	02-10-2008	US 2009023761 A1	22-01-2009
WO 2008118468	A	02-10-2008	NONE	